UK legislation to streamline gene-editing technology research is promising for innovation, but presents potential complications for IP, finds Sarah Speight.
- When alliances fail, is arbitration the answer? 24-02-2022
- Growing pains 03-08-2021
- CRISPR: A licence to heal 01-10-2019
- Brexit: The waiting game 01-10-2019
- IP portfolios: the five biggest headaches for in-house counsel 30-09-2019
Latest genetics news
Biotech company Illumina has asked a Delaware court to overturn a finding that it willfully infringed two DNA sequencing patents and must pay $334 million in damages.